SAN MATEO, Calif.--(BUSINESS WIRE)--Deltagen, Inc. (Pink Sheets: DGEN), a leading provider of drug discovery tools and services to the biopharmaceutical industry, today reported unaudited consolidated financial results for the three months ended September 30, 2012.
“Management’s Discussion and Analysis of Financial Conditions and Results of Operations”
Revenues: The Company’s consolidated revenues for the three months ended September 30, 2012 totaled $0.211 million. The revenues in the third quarter of 2012 were attributable primarily to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the Company’s DeltaOneTM program. The consolidated revenues for the period included $0.010 million for Xenopharm, Inc. (“Xenopharm”), a wholly-owned subsidiary of the Company. Benten BioServices' revenues and expenses are no longer consolidated with those of Deltagen and its wholly-owned subsidiaries, Xenopharm and Deltagen Research Laboratories, L.L.C. The application of the Equity Method of Accounting now reports Benten BioServices' operating results as a single line in Deltagen's financial statements, which reflect Deltagen's 43.8% ownership interest in Benten BioServices. The Equity Method of Accounting is described in the Company's Notes to Consolidated Financial Statements and Management’s Discussion and Analysis of Financial Conditions and Results of Operations, which are posted on the Company's website (www.deltagen.com).
Expenses: Total consolidated expenses for the three months ended September 30, 2012 were $0.258 million. The expenses in the third quarter of 2012 were attributable primarily to labor costs and other general and administrative expenses, including $0.061 million in royalty and commission expenses. As of September 30, 2012, the Company had incurred aggregate total royalties to Lexicon Pharmaceuticals, Inc. (“Lexicon”) of $5.702 million to a March 2005 settlement agreement between Lexicon and the Company. Under the settlement, the maximum aggregate amount of royalty payments due to Lexicon is $6.00 million. Accordingly, up to $0.298 million in contingent royalty payments remained owed to Lexicon as of September 30, 2012.
Net Income/Losses: Consolidated net losses before provision for income taxes for the three months ended September 30, 2012 were $0.581 million, which included a net loss of $0.047 million from operations and a recognized net loss of $0.534 million (43.8% of Benten BioServices' Net Operating Results) from investments made by the Company in Benten BioServices, Inc. ("Benten BioServices"), which was accounted for using the Equity Method of Accounting.
Cash, Cash Equivalents and Accounts Receivable: As of September 30, 2012, the Company had $0.187 million in consolidated cash and cash equivalents and $0.063 million in accounts receivable.
Major Events during Q3 2012:
Benten BioServices: Benten BioServices had received an aggregate total of $2.940 million in secured bridge financing between January and August 2012 ("Series A"). The Series A financing was led by Life Sciences Green House of Central Pennsylvania and closed on August 15, 2012, at which time Benten BioServices ceased being a wholly-owned subsidiary of Deltagen. Following the Series A closing, excluding Benten BioServices' stock options, Deltagen held 43.8% of the outstanding shares of Benten BioServices. Deltagen shall retain a seat on the board of directors of Benten BioServices solely representing Deltagen so long as it beneficially owns at least 10% of the outstanding common stock of Benten BioServices.
The unaudited consolidated financial statements for the third quarter of 2012, accompanying notes, and Management’s Discussion and Analysis of Financial Conditions and Results of Operations for such period will be posted on Deltagen’s website (www.deltagen.com).
Deltagen, Inc. is a provider of drug discovery tools to the biopharmaceutical industry, and offers access to its inventory of knockout mouse lines and related phenotypic data to enhance the efficiency of target validation and drug discovery. In addition, Deltagen offers target validation data in the areas of immunology and metabolic diseases. Deltagen's products and programs have been validated by customers and partners such as Eli Lilly & Co., GlaxoSmithKline, Merck & Co., Inc. and Pfizer Inc. Benten BioServices, Inc., based in Malvern, Pennsylvania, offers regulatory-compliant services designed to address specific requirements for critical stages in product development, including biosafety testing, raw materials testing, assay and process validation services, cell banking and characterization services, and technology platform-specific R&D support and consulting services. For more information on Deltagen, visit the Company's website at www.deltagen.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements about Deltagen’s future revenues, cash flows and operating results, first-party royalty obligations and first-party licenses and intellectual property, fund-raising efforts, Benten BioServices' business plans, as well as other matters that are not historical facts or information. These forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Deltagen’s ability to achieve its operational objectives and revenue projections, that may cause Deltagen’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important risk factors is contained in the Company's annual financial disclosure's “Management’s Discussion and Analysis of Financial Conditions and Results of Operations”, which can be found at Deltagen’s website at www.deltagen.com. Deltagen undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
CONSOLIDATED BALANCE SHEET
|Consolidated Balance Sheet|
|As of 9/30/12|
|Cash and cash equivalents||
|Accounts receivable, net||63|
|Prepaid expenses, deposits and deferred tax assets||69|
|Total current assets||
|Property and equipment, net||29|
|Investment in Benten BioServices, Inc. accounted for using the Equity Method||5,109|
|Non-current portion of deferred tax assets||1,586|
|Liabilities and Stockholders' Equity|
|Total long-term liabilities||$||-|
|Additional paid-in capital||232,533|
|Foreign currency translation adjustment||402|
|Total stockholders' equity||
|Total liabilities and stockholders' equity||
CONSOLIDATED INCOME STATEMENT
Consolidated Income Statements and
Statements of Retained Earnings
|For Quarter ended 9/30/12|
|Royalty and Commission Costs||61|
|Other Operating Costs||196|
|Income From Operations||$||(47||)|
|Income (Loss) from Benten BioServices, Inc. accounted for using the Equity Method||(534||)|
|Loss on disposal of assets||-|
|Total Other Income (Loss)||(534||)|
|Income before provision for income taxes||$||(581||)|
|Provision for income taxes|
|Current income tax expense||-|
|Deferred income tax expense||-|
|Adjustment for valuation allowance||-|
|Total income tax expense||-|
|Net Income (Loss)||$||(581||)|
|Retained earnings at beginning of period||(224,797||)|
|Retained earnings at end of period||$||(225,378||)|
CONSOLIDATED CASH FLOW
|Consolidated Cash Flows|
|For Quarter ended 9/30/12||Unaudited|
|Cash flows from operating activities:|
|Net Income (Loss)||$||(581||)|
|Adjustments to reconcile net income to net cash provided|
|by operating activities:|
|Stock-based compensation expense||-|
|Loss on disposal of fixed assets||-|
(Increase)/Decrease in operating assets
|Prepaid expenses, deposits and tax assets||209|
|Purchase of assets||-|
|Deferred tax assets||-|
Increase/(Decrease) in operating liabilities
|Change in goodwill||-|
|Benten stock issuance||-|
|Issuance of convertible note||-|
|Cumulative effect of equity method recognition||481|
|Net Increase/(Decrease) in cash||$||(167||)|
|Effect of foreign exchange rate change on cash and cash equivalents||-|
|Cash and cash equivalents, at beginning of period||354|
|Cash and cash equivalents, at end of period||187|